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Expanded Abstract 
Citation 
Wheeler AP, Bernard GR, Thompson BT, Schoenfeld D, 
Wiedemann HP, deBoisblanc B, Connors AF, Jr., Hite RD, 
Harabin AL. Pulmonary-artery versus central venous 
catheter to guide treatment of acute lung injury. N Engl J 
Med 2006;354:2213-2224 [1]. 
Background 
The balance between the benefits and the risks of 
pulmonary artery catheters (PACs) has not been 
established.   
Methods 
Objective: To assess the safety and efficacy of PAC-guided 
vs. central venous catheter-guided management in reducing 
mortality and morbidity in patients with established acute 
lung injury (ALI). 
Design: Randomized, controlled, non-blinded trial. 
Setting: 36 centers in the United States and 2 in Canada. 
Subjects: 1000 patients with established acute lung injury 
of less than 48 hours duration. Subjects were excluded if 
they already had a PAC in place or had chronic conditions 
that could independently influence survival, impair weaning, 
or compromise compliance with the protocol, such as 
dialysis dependence, severe lung or neuromuscular 
disease, or terminal illness. 
Intervention: Subjects were randomized to hemodynamic 
management guided by a PAC or a CVC using an explicit 
management protocol.   
Outcomes: Hospital mortality during the first 60 days before 
discharge home was the primary outcome. Secondary 
outcomes included ventilator-free days, intensive care unit-
free days, organ failure-free days, and adverse events.   
 
Results  
The groups had similar baseline characteristics. The rates 
of death during the first 60 days before discharge home 
were similar in the PAC and CVC groups (27.4 percent and 
26.3 percent, respectively; P=0.69; absolute difference, 1.1 
percent; 95 percent confidence interval, -4.4 to 6.6 percent), 
as were the mean (+/-SE) numbers of both ventilator-free 
days (13.2+/-0.5 and 13.5+/-0.5; P=0.58) and days not 
spent in the intensive care unit (12.0+/-0.4 and 12.5+/-0.5; 
P=0.40) to day 28. PAC-guided therapy did not improve 
these measures for subgroup of patients in shock at the 
time of enrollment. There were no significant differences 
between groups in lung or kidney function, rates of 
hypotension, ventilator settings, or use of dialysis or 
vasopressors. Approximately 90 percent of protocol 
instructions were followed in both groups, with a 1 percent 
rate of crossover from CVC- to PAC-guided therapy. Fluid 
balance was similar in the two groups, as was the 
proportion of instructions given for fluid and diuretics. 
Dobutamine use was uncommon. The PAC group had 
approximately twice as many catheter-related complications 
(predominantly arrhythmias), though rates per catheter 
insertion were similar between groups. 
Conclusions 
PAC-guided therapy did not improve survival or organ 
function but was associated with more complications than 
CVC-guided therapy. These results, when considered with 
those of previous studies, suggest that the PAC should not 
be routinely used for the management of acute lung injury. 
(ClinicalTrials.gov number, NCT00281268.). 
Commentary 
The balloon-tipped, flow-directed, pulmonary artery catheter 
(PAC), introduced by Swan in 1970 [2], made bedside 
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assessment of hemodynamics available to the masses. 
Because of the obvious appeal of PAC-derived data, 
widespread adoption ensued. Concern emerged in the 
1990s that PAC use might be associated with increased 
mortality. At least six randomized controlled trials of PAC 
use in general or specialist intensive care have been 
conducted, none of which found harm or benefit for PAC 
use [3-8]. These trials were criticized for a variety of 
reasons, including small size, selection bias, lack of a 
central venous catheter (CVC)-based comparison group, or 
the possibility that clinician participants may not have used 
PAC data “correctly”, either due to incorrect interpretation or 
because treatment was not explicitly directed by a protocol.  
The current study, the NIH-funded Fluid and Catheter 
Treatment Trial (FACTT), was designed to address the 
limitations of prior studies [1]. The goal of FACTT was to 
evaluate the safety and efficacy of PAC-guided versus 
CVC-guided management in reducing mortality and 
morbidity in patients with established ALI. Using a factorial 
design, this trial also compared liberal versus conservative 
fluid management [9]. FACTT was an efficacy trial where 
the interpretation and subsequent management decisions 
were entrained within tightly administered protocols. FACTT 
generated considerable controversy even before its 
completion, because of disagreement over what constitutes 
a safe approach to ventilator management in the critically ill 
[10]. The finding that PAC-guided therapy did not improve 
survival or organ function but was associated with more 
complications than CVC-guided therapy generated its share 
of controversy [11,12] as did the study’s other main finding, 
which supported the use of a conservative fluid 
management strategy in patients with ALI [9,11,13-16]. 
FACTT was a well-conducted trial with a number of 
strengths. All study personnel underwent extensive training 
in measurement of intravascular pressure to avoid 
misinterpretation of PAC or CVC-derived data. Furthermore, 
pressure tracings underwent centralized review. Protocol 
compliance, which was monitored twice daily, was high 
(~90% of all instructions followed) and similar between 
groups. Follow-up was complete, with the exception of one 
subject that withdrew consent before study-related 
treatment was received. The analysis was conducted on an 
intent-to-treat basis and, importantly, looked for evidence of 
interaction between type of catheter used and fluid 
management strategy. No interaction was found, meaning 
that a PAC was not beneficial regardless of the fluid 
management strategy employed. 
Limitations of the trial include that of 11,511 subjects 
screened, 10,511 (91%) were excluded. Significant reasons 
for exclusion were current PAC use (21%), chronic lung 
disease (14%), dialysis (9%), chronic liver disease (7%), 
and acute myocardial infarction (6%). The first of these 
raises the possibility that clinicians may have already 
inserted a PAC in patients that “needed” one, leaving only 
those patients less likely to benefit from PAC insertion to be 
enrolled in the clinical trial, a form of selection bias. 
However, it seems unlikely that clinicians were that 
proficient in determining who would or would not benefit 
from a PAC. The majority of subjects were enrolled in 
medical ICUs. This and the remaining exclusion criteria limit 
the generalizeability of study results, in that surgical patients 
or those with excluded medical conditions might still benefit 
from the titrated hemodynamic management a PAC offers. 
Though subjects were enrolled early (≤48 hours) in the 
course of ALI, first study-related interventions were not 
received until a mean of 25 hours after qualification for ALI 
and 44 hours after ICU admission. Therefore, these findings 
do not inform the debate regarding early goal-directed 
therapy, such as for resuscitation in the first 6 hours of 
septic shock [17]. 
These limitations not withstanding, will the results of this 
study lead to dramatic changes in clinical practice? The 
answer, strangely enough, may be no. Across a variety of 
disease states, PAC use is already undergoing precipitous 
decline, as recently reported [18] and as many clinicians 
have no doubt observed. With decreasing PACs use, 
maintaining competency will become increasingly difficult, 
with significant implications for physicians, nurses, and 
especially trainees. Decreasing PAC use may represent 
more judicious PAC use or, perhaps, substitution of less 
invasive monitoring technologies. As pointed out by 
Rubenfeld and colleagues [19], we must alert to this second 
possibility, in that titrating care based on data obtained from 
these new devices is itself of unproven benefit. 
Recommendation 
PACs should not be routinely used to guide hemodynamic 
management in the ICU. It remains possible that their use 
may benefit select patient groups. Clinicians must weigh 
carefully the perceived benefits, which may be largely 
intangible, against the small, but non-zero, risk of harm to 
the patient. The safety and efficacy of alternative 
hemodynamic monitors must be tested, if the mistakes 
associated with the widespread adoption of the PAC are to 
be avoided. 
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